- Obesity and Metabolism
- A Novel Long-Acting Glucagon-Like Peptide-1 Agonist with Improved Efficacy in Insulin Secretion and β-Cell Growth
-
Hee Young Kim, Jong-Ik Hwang, Mi Jin Moon, Jae Young Seong
-
Endocrinol Metab. 2014;29(3):320-327. Published online September 25, 2014
-
DOI: https://doi.org/10.3803/EnM.2014.29.3.320
-
-
4,356
View
-
49
Download
-
10
Web of Science
-
11
Crossref
-
 Abstract
 PDF PubReader
- Background
Glucagon-like peptide-1 (GLP-1) is an incretin hormone produced by cleavage of proglucagon in intestinal L-cells. In the pancreas, GLP-1 stimulates post-prandial insulin secretion, promotes insulin biosynthesis, and improves insulin sensitivity. Because of its insulinotropic activity, GLP-1 has been considered a good candidate drug for treatment of diabetes mellitus. However, clinical use of GLP-1 has been limited by its short half-life, as a result of rapid degradation by dipeptidyl peptidase-IV (DPP-IV). MethodsWe designed a novel GLP-1 analog, Xenopus GLP-1 (xGLP)-E4. The Ala residue in the second position of xGLP was replaced with a Ser residue to increase the half-life in the body. The C-terminal tail of exendin-4 was added to enhance the binding affinity for the GLP-1 receptor (GLP1R). The potency of GLP-1 and its analogs was determined by luciferase assay. The stability of GLP1R agonists was evaluated by determining the activity of agonists that had been preincubated in the presence of fetal bovine serum, which contains innate DPP-IV activity. The effects of xGLP-E4 on insulin secretion and β-cell growth were investigated using insulin enzyme-linked immunosorbent assay and cell counting. ResultsxGLP-E4 exhibited improved stability against DPP-IV activity and increased potency to GLP1R, compared with GLP-1. An increase in glucose-dependent insulin secretion was observed in xGLP-E4-treated pancreatic β-cells. The effect of xGLP-E4 on β-cell growth was greater than that of GLP-1. ConclusionWe developed a novel GLP-1 analog, xGLP-E4, that shows prolonged longevity and improved efficacy. This analog is a potential candidate for treatment of type 2 diabetes.
-
Citations
Citations to this article as recorded by  - Novel GLP-1(28–36) amide-derived hybrid peptide A3 with weight loss and hypoglycemic activities
Chen Wang, Binbin Gong, Qianqian Zhu, Jing Han, Lidan Sun
European Journal of Pharmacology.2023; 961: 176200. CrossRef - Intranasal Delivery of a Methyllanthionine-Stabilized Galanin Receptor-2-Selective Agonist Reduces Acute Food Intake
Anneke Kuipers, Márta Balaskó, Erika Pétervári, Andreas Koller, Susanne M. Brunner, Gert N. Moll, Barbara Kofler
Neurotherapeutics.2021; 18(4): 2737. CrossRef - Low-Dose Decitabine Assists Human Umbilical Cord-Derived Mesenchymal Stem Cells in ProtectingβCells via the Modulation of the Macrophage Phenotype in Type 2 Diabetic Mice
Jing Xue, Yu Cheng, Haojie Hao, Jieqing Gao, Yaqi Yin, Songyan Yu, Junyan Zou, Jiejie Liu, Qi Zhang, Yiming Mu
Stem Cells International.2020; 2020: 1. CrossRef - DR10601, a novel recombinant long-acting dual glucagon-like peptide-1 and glucagon receptor agonist for the treatment of obesity and type 2 diabetes mellitus
W. Wang, X. Wen, W. Duan, X. Wang, Y. Chen, J. Dong, Z. Yang, J. Fang, Z. Zhou, G. Yao, Y. Fang, Y. Huang
Journal of Endocrinological Investigation.2020; 43(5): 653. CrossRef - Evolutionary and Comparative Genomics to Drive Rational Drug Design, with Particular Focus on Neuropeptide Seven-Transmembrane Receptors
Michael Furlong, Jae Young Seong
Biomolecules & Therapeutics.2017; 25(1): 57. CrossRef - Comparison of exenatide and acarbose on intra-abdominal fat content in patients with obesity and type-2 diabetes: A randomized controlled trial
Li Shi, Jing Zhu, Ping Yang, Xiaoqiang Tang, Wenlong Yu, Changjie Pan, Moyu Shen, Dalong Zhu, Jinluo Cheng, Xinhua Ye
Obesity Research & Clinical Practice.2017; 11(5): 607. CrossRef - Mesenchymal stem cell therapy in type 2 diabetes mellitus
Li Zang, Haojie Hao, Jiejie Liu, Yijun Li, Weidong Han, Yiming Mu
Diabetology & Metabolic Syndrome.2017;[Epub] CrossRef - Exendin-4 Inhibits Hepatic Lipogenesis by Increasing β-Catenin Signaling
Mi Hae Seo, Jinmi Lee, Seok-Woo Hong, Eun-Jung Rhee, Se Eun Park, Cheol Young Park, Ki Won Oh, Sung Woo Park, Won-Young Lee, Catherine Mounier
PLOS ONE.2016; 11(12): e0166913. CrossRef - Development of Spexin-based Human Galanin Receptor Type II-Specific Agonists with Increased Stability in Serum and Anxiolytic Effect in Mice
Arfaxad Reyes-Alcaraz, Yoo-Na Lee, Gi Hoon Son, Nam Hoon Kim, Dong-Kyu Kim, Seongsik Yun, Dong-Hoon Kim, Jong-Ik Hwang, Jae Young Seong
Scientific Reports.2016;[Epub] CrossRef - Articles in 'Endocrinology and Metabolism' in 2014
Won-Young Lee
Endocrinology and Metabolism.2015; 30(1): 47. CrossRef - Biased signalling: the instinctive skill of the cell in the selection of appropriate signalling pathways
Ying Liu, Yang Yang, Richard Ward, Su An, Xiao-Xi Guo, Wei Li, Tian-Rui Xu
Biochemical Journal.2015; 470(2): 155. CrossRef
- Molecular Mechanism of GnRH Interaction with GnRH Receptor in an Evolutionary Viewpoint.
-
Jae Young Seong, Hyuk Bang Kwon
-
J Korean Endocr Soc. 2000;15(6):779-790. Published online January 1, 2001
-
-
-
Abstract
- No Abstract Available.
|
KES
